RDY - Dr. Reddy’s Laboratories Ltd ADR

Exchange: USA Stocks • Country: India • Currency: USD • Type: Common Stock • ISIN: US2561352038

Generic Medicines, Active Pharmaceutical Ingredients, Biologics

Dr. Reddy's Laboratories Limited is a global pharmaceutical company that operates through three main segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others.

The Global Generics segment is responsible for manufacturing and marketing a wide range of prescription and over-the-counter pharmaceutical products, including branded and generic finished dosages that are therapeutically equivalent to branded formulations. This segment also includes the company's biologics business, which involves the development and production of complex biological molecules used to treat various diseases.

The PSAI segment is focused on manufacturing and marketing active pharmaceutical ingredients (APIs) and intermediates, which are essential components used in the production of finished pharmaceutical products. This segment also provides contract research services, where the company collaborates with clients to develop and manufacture APIs and steroids according to their specific requirements.

The Others segment is involved in developing innovative therapies in areas such as oncology and inflammation, as well as researching and developing differentiated formulations that can improve patient outcomes. This segment also provides digital healthcare and information technology-enabled business support services, which help to streamline healthcare operations and improve patient care.

Dr. Reddy's Laboratories offers a diverse range of products that cater to various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. With a strong presence in over 25 countries, the company is committed to providing affordable and innovative healthcare solutions to patients around the world.

Founded in 1984, Dr. Reddy's Laboratories is headquartered in Hyderabad, India, and has established itself as a leading player in the global pharmaceutical industry. For more information, please visit the company's website at https://www.drreddys.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for RDY - Dr. Reddy’s Laboratories Ltd ADR

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for RDY - Dr. Reddy’s Laboratories Ltd ADR

RDY Stock Overview

Market Cap in USD 13,562m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC SubIndustry Pharmaceuticals
TER 0.00%
IPO / Inception 2001-04-11

RDY Stock Ratings

Growth 5y 59.0
Fundamental 54.4
Dividend 52.7
Rel. Performance vs Sector 0.67
Analysts 3.00/5
Fair Price Momentum 81.49 USD
Fair Price DCF 2848.93 USD

RDY Dividends

Dividend Yield 12m 0.59%
Yield on Cost 5y 1.33%
Dividends CAGR 5y 28.02%
Payout Consistency 93.9%

RDY Growth Ratios

Growth 12m 18.75%
Growth Correlation 12m 42%
Growth Correlation 3m 54%
CAGR 5y 17.57%
CAGR/Mean DD 5y 1.42
Sharpe Ratio 12m 0.67
Alpha vs SP500 12m 5.77
Beta vs SP500 5y weekly 0.49
ValueRay RSI 83.75
Volatility GJR Garch 1y 21.31%
Price / SMA 50 10.53%
Price / SMA 200 14.43%
Current Volume 250.3k
Average Volume 20d 249.8k

External Links for RDY Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of RDY stocks?
As of July 27, 2024, the stock is trading at USD 81.22 with a total of 250,264 shares traded.
Over the past week, the price has changed by +3.97%, over one month by +13.44%, over three months by +9.61% and over the past year by +18.97%.
What are the forecast for RDY stock price target?
According to ValueRays Forecast Model, RDY Dr. Reddy’s Laboratories Ltd ADR will be worth about 88 in July 2025. The stock is currently trading at 81.22. This means that the stock has a potential upside of +8.36%.
Issuer Forecast Upside
Wallstreet Target Price 80.2 -1.32
Analysts Target Price 70.1 -13.7
ValueRay Target Price 88 8.36